oral glp-1 agonist FDA just approved orforglipron (Foundayo), Eli Lilly's receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Orforglipron: The Oral Non-Peptide GLP-1

In vivo experiments further demonstrated that Irisin-loaded bone marrow mesenchymal stem cell-derived exosomes significantly inhibited activation of the YAP/EGR1/ACSL4 signaling pathway in the brains of middle cerebral artery occlusion (MCAO) mice, suppressed ferroptosis and lipid peroxidation, thereby mitigating ischemic brain injury ( In vitro experiments further confirmed that FGF21 protected HT22 cells from OGD/R-induced oxidative stress and ferroptosis, thereby attenuating neuronal injury (Zhao et al., 2025c)

If eligible, theyll create a care plan tailored to your needs

Telli, M., Witteles, R., Fisher, G., & Srinivas, S

It fights off hydroxyl radicals, hypochlorous acid, peroxyl radicals, superoxide, singlet oxygen, and peroxynitrite